If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
NEW YORK–(HSMN NewsFeed)–ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY ), and Bristol-Myers Squibb Company (NYSE: BMY ) today announced that the companies received a complete response letter from the U.S. Food and Drug Ad…
Biopharmaceuticals, Oncology, FDA
Bristol-Myers Squibb, ImClone Systems, ERBITUX, cetuximab, head and neck cancer
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.
NEW YORK–(HSMN NewsFeed)–ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY ), and Bristol-Myers Squibb Company (NYSE: BMY ) today announced that the companies received a complete response letter from the U.S. Food and Drug Ad…
Biopharmaceuticals, Oncology, FDA
Bristol-Myers Squibb, ImClone Systems, ERBITUX, cetuximab, head and neck cancer
0 Comments on “ImClone Systems and Bristol-Myers Squibb Update Status of First-Line Squamous Cell Carcinoma of the Head and Neck Supplemental Biologics Application for ERBITUX(R) in U.S.”
Leave a Comment